X axis : Stocks Price Correlation Coefficient Y axis : Quantity of stocks May-2016 1,000 Day Parameter 4,338 NYSE Stocks Price Analysis This stock mode of correlation coefficient is 0.8 In other words, the correlation coefficient of the other stocks
Does anyone see ABBV buying TGTX? I'll be straight up here, I own TGTX. They can increase the efficacy of Imbruvica from 47% to 80% soI think either ABBV or J&J will want them. I owned PCYC all the way from single digits until buyout, I'm excited to see what the next step will be.
looks like a patent suit decision was not good news
Just when this stock looked ready for its next leg up we take a 2.5% haircut............on no news!
This Fund#$%$ Gained 200% In A Year And Why No One Knows About It$MDCO $BIIB $ABBVhttp://www.insidermonkey.com/blog/this-funds-picks-gained-200-in-a-year-and-why-no-one-knows-about-it-581306/?utm_source=Stocktwits&utm_medium=Social&utm_campaign=dnan
Charles A. Henriques ( Globally Popularized @ Linkedin.com )
NeurogesX Inc.15% owner. QUTENZA developer - Non-Opioid Pain Therapies For Unmet Needs In Neuropathic Pain Neuropathic Pain Investor Sacred Heart University Fairfield CT BS/BA Business Administration
San Francisco Bay Area: That Richard Gere look and 1845 Connections @ linkined.com
Charles A. Henriques increased stake in NeurogesX, Inc. Filed SC 13G/A form with U.S. Securities and Exchange Commission on February 13, 2017. Amount beneficially owned: 4,966,649 NGSX shares. CUSIP# 641252101.
Form 13G is used when the filer owns between 5% and 20% of the company and plans to hold it only as a passive investor. If the filler intend to exert control and if the stake’s size exceeds 20%, then a 13D must be filed. Therefore, activist investors and practices such as: hostile takeovers, company breakups, and other “change of control” events, are not permitted by 13G filers.
NeurogesX Inc. (NeurogesX), is a specialty pharmaceutical company focused on developing and commercializing a portfolio of novel non-opioid, Pain Management Therapies to address unmet medical needs. Qutenza the Company’s first commercial product, has FDA approval, available in USA by Acorda Therapeutics Inc. EU approval in 2009 and available at Astellas Pharma in all 28 European countries.
Qutenza is a dermal delivery system designed to topically administer capsaicin to treat certain neuropathic pain conditions. Approved by the FDA for the management of neuropathic pain associated with postherpetic neuralgia (PHN). In September 2015, the European Commission approved a label extension for Qutenza to include diabetic patients with neuropathic pain, adding more value to product.
QUTENZA has a Patented Synthetic Capsaicin that works faster and better than Lyrica according to a study published in the European Journal of Pain, funded by Astellas Pharma Europe Ltd,
Lyrica is Pfizer’s top selling drug with annual worldwide sales of over $5 billion.
Grunenthal News 12 -12 -17 Acquiring Commercialization Rights for Qutenza® From Astellas.
The Grünenthal Group is an independent, family-owned, international research-based pharmaceutical company headquartered in Aachen,
After billion dollars spent on PARP inhibitor veliparib, the least potent of all PARP inhibitors in clinical trial, Abbv met its big failure today, FDA rejects the Veliparib. But it would not be too late to acquire either of two already FDA approved PARP inhibitors or both to
Anyone know what is going on with ABBV today, 4/18/17?
There could be a short term bounce. Technical 72% chance bullish at foxchart.
Option price doesn't make sense:
I noticed the ex-dividend is 4/13 and I think we are in for a healthy dividend announcement. It dropped to $64.97. Would be a return of approx. .65 be out of expectations? If the day's drop is indicative of the dividend payout then isn't this not a reach?
What's the problem with this stock.......its been on a tailspin for a while now
Cannot believe you changed the format on the summaries...... stocks.... you all can stick it.
ABBV should buy Fitbit.
does any one knows why ABBV shows the price down 3.83 re market???
wow look at the premarket .. down 3.83 , that's some fool that doesn't know how it works and put in a sale if the stock ever went that low. IN the morning some guy just offered even lower and then took his shares.
Abbv got a big lift from all the great boosts by analysts . I guess its normal there is some profit taking. Then the health sector got dragged down last week . An hour into Mondays trading we will see which way the wind is blowing.
Its morning and the boys who want in cheaper are trading a few shares before the open to drag the price down .